Guinan, K.; Mathurin, K.; Au, Y.; Schuh, A.C.; Bui, C.N.; Chai, X.; Lachaine, J.
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis. Curr. Oncol. 2022, 29, 7524-7536.
https://doi.org/10.3390/curroncol29100592
AMA Style
Guinan K, Mathurin K, Au Y, Schuh AC, Bui CN, Chai X, Lachaine J.
Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis. Current Oncology. 2022; 29(10):7524-7536.
https://doi.org/10.3390/curroncol29100592
Chicago/Turabian Style
Guinan, Kimberly, Karine Mathurin, Yunghan Au, Andre C. Schuh, Cat N. Bui, Xinglei Chai, and Jean Lachaine.
2022. "Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis" Current Oncology 29, no. 10: 7524-7536.
https://doi.org/10.3390/curroncol29100592
APA Style
Guinan, K., Mathurin, K., Au, Y., Schuh, A. C., Bui, C. N., Chai, X., & Lachaine, J.
(2022). Venetoclax in Combination with Azacitidine for the Treatment of Newly Diagnosed Acute Myeloid Leukemia: A Canadian Cost–Utility Analysis. Current Oncology, 29(10), 7524-7536.
https://doi.org/10.3390/curroncol29100592